Modafinil vs Sabroxy (Oroxylum indicum)

Mechanism

Atypical eugeroic (wakefulness-promoting agent) that primarily inhibits the dopamine transporter (DAT), increasing extracellular dopamine in the prefrontal cortex and nucleus accumbens. This primary action cascades through multiple systems: indirect activation of orexinergic neurons in the lateral hypothalamus via potentiation of glutamatergic transmission; downstream stimulation of histaminergic neurons in the tuberomammillary nucleus (via orexin-mediated disinhibition of GABAergic inputs); and enhancement of norepinephrine release in the locus coeruleus. The net effect is broad-spectrum arousal without the peripheral sympathomimetic effects of classical stimulants.

Standard Dosing

100-200 mg once daily (for educational context only — prescription medication in most jurisdictions)

Timing

Early morning to avoid insomnia; 1 hour before desired peak alertness. With or without food (food slows absorption by ~1 hour but does not reduce bioavailability). Half-life is approximately 12-15 hours.

Cycle Duration

Not typically cycled in clinical use. Some off-label users cycle to maintain sensitivity (5 days on, 2 off; or as-needed use).

Side Effects

• Headache (most common)
• Nausea
• Anxiety/nervousness
• Insomnia
• Dry mouth
• Dizziness
• Upper respiratory tract infection
• Diarrhea
• Stevens-Johnson syndrome (very rare but serious)

Contraindications

• Mitral valve prolapse or left ventricular hypertrophy
• Severe hepatic impairment
• Severe anxiety or psychotic disorders
• History of substance abuse (mild abuse potential)
• Hypersensitivity to modafinil or armodafinil
• Pregnancy (Category C)

Best Stacking Partners

Mechanism

Contains oroxylin A — a flavonoid that inhibits PDE (phosphodiesterase), increases BDNF, and modulates dopamine signaling. Enhances focus and motivation without stimulant side effects. Also acts as a mild MAO-B inhibitor, preserving dopamine levels.

Contraindications

• Concurrent MAO inhibitors